United States Proton Therapy Market Report 2022 to 2027: Featuring IBA Proton Therapy, Varian Medical Systems and Elekta – ResearchAndMarkets.com

United States Proton Therapy Market Report 2022 to 2027: Featuring IBA Proton Therapy, Varian Medical Systems and Elekta - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “United States Proton Therapy Market, Size, Forecast 2022-2027, Industry Trends, Impact of COVID-19, Growth, Opportunity Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

The United States Proton Therapy Market is expected to reach US$ 1.8 Billion by 2027.

Companies Mentioned

IBA Proton Therapy

Varian Medical Systems

Elekta

Proton therapy is an excellent treatment alternative for numerous patients, especially those with tumours close to vital organs. Besides, for children, those most vulnerable and susceptive to the damage of conventional radiation therapy, proton therapy offers less radiation exposure while demoting side effects. In addition, proton therapy is a high-tech option for X-ray radiation. With online image guidance, a scanning beam of proton radiation advises greater precision to destroy carcinogenic cells, sparing adjacent healthy tissue with more infrequent side effects.

COVID-19 Impact on United States Proton Therapy Industry:

Despite the outbreak of COVID-19 worldwide, the proton therapy market has increased at a constant speed. It was only stopped for a brief period in the initial months of the pandemic outbreak but later resumed to take care of the cancer patients and radiation therapies patients in the United States; many procedures have been finalized to help the patients with therapies. Such as, many implementations and algorithms have been carried out to safeguard the radiation patients from COVID-19.

United States Proton Therapy Market will grow with a CAGR of 8.5% during the period 2021-2027

The rise of the proton therapy industry in the United States is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access along with premium pricing. As per the analysis, United States Proton Therapy Market Size was US$ 1.1 Billion post-pandemic recoveries in 2021.

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Market (Actual & Potential) – United States Proton Therapy Market

5.1 Actual Proton Therapy Market

5.2 Potential Proton Therapy Market

6. Number of Patients – United States Proton Therapy

6.1 Actual Numbers

6.2 Potential Numbers

7. Cancer Types – United States Proton Therapy Market

7.1 Central Nervous System Tumors

7.2 Intraocular Melanomas Cancer

7.3 Pituitary Neoplasms Cancer

7.4 Base of Skull / Axial Skeleton Cancer

7.5 Head and Neck Cancer

7.6 Lung Cancer

7.7 Retroperitoneal Sarcoma Cancer

7.8 Pediatric Cancer Cases (Up to Age 18)

7.9 Gastrointestinal Tract Cancer

7.10 Urinary Tract Cancer

7.11 By Female Pelvic Organs Cancer

7.12 Prostate Cancer

7.13 Breast Cancer

7.14 Other Cancer

8. Cancer Types – United States Proton Therapy Patients Numbers

8.1 Central Nervous System Tumors

8.2 Intraocular Melanomas Cancer

8.3 Pituitary Neoplasms Cancer

8.4 Base of Skull / Axial Skeleton Cancer

8.5 Head and Neck Cancer

8.6 Lung Cancer

8.7 Retroperitoneal Sarcoma Cancer

8.8 Pediatric Cancer (Up to Age 18)

8.9 Gastrointestinal Tract Cancer

8.10 Urinary Tract Cancer

8.11 Female Pelvic Organs Cancer

8.12 Prostate Cancer

8.13 Breast Cancer

8.14 Other Cancer

9. United States – List of Proton Therapy Centers

9.1 Operating Proton Therapy Centers

9.2 Under-Construction Therapy Centers

9.3 Planning Proton Therapy Centers

10. Proton Therapy – Reimbursement Policies

10.1 Proton Therapy Reimbursement Policies for Patients

10.2 Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers

11. Components of a Standard Proton Therapy Center

11.1 Proton Accelerator

11.1.1 Synchrotrons (example: LLUMC at Loma Linda)

11.1.2 Cyclotrons (example: MGH Boston)

11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)

11.1.4 Linacs (Rome)

11.1.5 H-minus Synchrotrons

11.1.6 Separated Sector Cyclotrons

11.1.7 Super-conducting Cyclotrons

11.1.8 Fast Cycling Synchrotron

11.2 Beam Transport System

11.3 Beam Delivery System

11.3.1 The Passive Scattering Technique

11.3.2 Beam Scanning

11.4 Nozzle

11.4.1 Single Scattering

11.4.2 Double Scattering

11.4.3 Uniform Scanning Nozzle

11.4.4 Pencil Scanning Nozzle

11.5 Treatment Planning System

11.6 Image Viewers

11.7 Patient Positioning System (PPS)

11.8 Human Resource

12. Porters Five Forces

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13. Company Analysis

13.1 IBA Proton Therapy

13.1.1 Overview

13.1.2 Recent Developments

13.1.3 Sales Analysis

13.2 Varian Medical Systems

13.2.1 Overview

13.2.2 Recent Developments

13.2.3 Sales Analysis

13.3 Elekta

13.3.1 Overview

13.3.2 Recent Developments

13.3.3 Sales Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ypcxni

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.